130 related articles for article (PubMed ID: 4084732)
1. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.
Merrick MV; Ding CL; Chisholm GD; Elton RA
Br J Urol; 1985 Dec; 57(6):715-20. PubMed ID: 4084732
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
[TBL] [Abstract][Full Text] [Related]
3. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
[TBL] [Abstract][Full Text] [Related]
4. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
[TBL] [Abstract][Full Text] [Related]
5. Bone scintigraphy, radiographic survey and prostatic acid phosphatase in patients with prostatic carcinoma. A comparison of sensitivity.
Reikerås O; Due J; Sundsfjord JA
Int Urol Nephrol; 1988; 20(1):51-4. PubMed ID: 3283071
[TBL] [Abstract][Full Text] [Related]
6. Bone scanning and plasma phosphatases in carcinoma of the prostate.
O'Donoghue EP; Constable AR; Sherwood T; Stevenson JJ; Chisholm GD
Br J Urol; 1978 May; 50(3):172-7. PubMed ID: 753455
[TBL] [Abstract][Full Text] [Related]
7. [Bone scintigraphy, plasma ALP, TAP and PAP in patients with prostatic cancer].
Imamura A; Hoshi H; Jinnouchi S; Samejima M; Watanabe K
Kaku Igaku; 1988 Feb; 25(2):177-81. PubMed ID: 3386031
[No Abstract] [Full Text] [Related]
8. Bone imaging and serum phosphatases in prostatic carcinoma.
Bishop MC; Hardy JG; Taylor MC; Wastie ML; Lemberger RJ
Br J Urol; 1985 Jun; 57(3):317-24. PubMed ID: 4005501
[TBL] [Abstract][Full Text] [Related]
9. [Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase (PAP) in blood by PAP RIA kit "EIKEN" (author's transl)].
Kida T; Higuchi Y
Kaku Igaku; 1981 Aug; 18(7):907-15. PubMed ID: 7321322
[No Abstract] [Full Text] [Related]
10. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
Kida T; Higuchi Y
Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
[TBL] [Abstract][Full Text] [Related]
11. Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis.
Imai K; Tomaru Y; Ohnuki T; Yamanaka H; Sakai H; Kanetake H; Minami Y; Nomata K; Saito Y
Cancer; 1992 Jun; 69(12):2983-9. PubMed ID: 1591692
[TBL] [Abstract][Full Text] [Related]
12. Clinical study on prognosis of metastatic prostate cancer based on extent of disease on pretreatment bone scintigraphy.
Fuse H; Mizuno I; Yokoyama T; Sakamoto M; Katayama T
Int Urol Nephrol; 1995; 27(5):567-74. PubMed ID: 8775041
[TBL] [Abstract][Full Text] [Related]
13. The role of bone scanning in the assessment of prostatic carcinoma.
McGregor B; Tulloch AG; Quinlan MF; Lovegrove F
Br J Urol; 1978 May; 50(3):178-81. PubMed ID: 753456
[TBL] [Abstract][Full Text] [Related]
14. The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer.
Killian CS; Vargas FP; Pontes EJ; Beckley S; Slack NH; Murphy GP; Chu TM
Prostate; 1981; 2(2):187-206. PubMed ID: 7301655
[TBL] [Abstract][Full Text] [Related]
15. Audit and its impact in the management of advanced prostatic cancer.
Rana A; Chisholm GD; Christodoulou S; McIntyre M; Elton RA
Br J Urol; 1993 Oct; 72(4):478-83. PubMed ID: 8261306
[TBL] [Abstract][Full Text] [Related]
16. [Phosphatases and bone scan in prostatic cancer].
Urrutia M; Montero J; Grade J; Llopis M
Actas Urol Esp; 1977; 1(4):207-12. PubMed ID: 567001
[No Abstract] [Full Text] [Related]
17. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of routine follow-up examinations in patients with metastatic cancer of the prostate under hormone treatment.
Fosså SD; Heilo A; Lindegaard M; Skinningrud A; Ous S
Eur Urol; 1983; 9(5):262-6. PubMed ID: 6628467
[TBL] [Abstract][Full Text] [Related]
19. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.
Gerber G; Chodak GW
Urology; 1991 May; 37(5):418-22. PubMed ID: 2024388
[TBL] [Abstract][Full Text] [Related]
20. Scintigraphic changes in bone metastasis from prostate cancer after hormonal therapy--comparison with tumor markers and bone X-ray.
Koizumi K; Uchiyama G; Komatsu H
Ann Nucl Med; 1994 Nov; 8(4):225-30. PubMed ID: 7535550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
